Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs

Fineline Cube Apr 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Medical Device

Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries

Fineline Cube Apr 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment

Fineline Cube Apr 21, 2023

Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in...

Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs

Fineline Cube Apr 21, 2023

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial

Fineline Cube Apr 21, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Company Deals Drug

Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results

Fineline Cube Apr 20, 2023

Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Paclitaxel-Coated Balloon Dilation Catheter

Fineline Cube Apr 20, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy

Fineline Cube Apr 20, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials

Fineline Cube Apr 20, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 20, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Drug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment

Fineline Cube Apr 20, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...

Company Drug

Walvax Biotechnology’s RQ3013 mRNA Vaccine Shows Efficacy in Phase III Study

Fineline Cube Apr 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the efficacy interim results of a...

Policy / Regulatory

NMPA’s 2022 Drug Supervision Report: Clinical Trials and Market Filings on the Rise

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has released its “Annual Drug Supervision and Administration Statistics...

Company Medical Device

Alcon Laboratories’ Innovative Intraocular Lens Approved by China’s NMPA

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has granted import approval to US firm Alcon Laboratories,...

Company Drug

Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma

Fineline Cube Apr 19, 2023

Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...

Company Deals

EOC Pharma Group Partners with China National Accord Medicines for Distribution Rights

Fineline Cube Apr 19, 2023

China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord...

Company Deals

Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform

Fineline Cube Apr 19, 2023

Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...

Company Deals

Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System

Fineline Cube Apr 19, 2023

Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens...

Company Drug

Shandong Jincheng Pharmaceutical Initiates Phase II Study for LT-01 Antibacterial Drug

Fineline Cube Apr 19, 2023

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), China’s largest cephalosporin manufacturer, has announced receiving...

Company Deals

RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System

Fineline Cube Apr 19, 2023

RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...

Posts pagination

1 … 557 558 559 … 688

Recent updates

  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
  • Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
  • Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.